GAMIFANT is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Novimmune Sa. The primary component is Emapalumab.
| Product ID | 72171-501_3b952566-94f7-494a-ba9c-044799721b93 |
| NDC | 72171-501 |
| Product Type | Human Prescription Drug |
| Proprietary Name | GAMIFANT |
| Generic Name | (emapalumab-lzsg) |
| Dosage Form | Injection |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2018-11-20 |
| Marketing Category | BLA / BLA |
| Application Number | BLA761107 |
| Labeler Name | NovImmune SA |
| Substance Name | EMAPALUMAB |
| Active Ingredient Strength | 10 mg/2mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2019-12-31 |
| Marketing Start Date | 2018-11-20 |
| Marketing End Date | 2021-11-30 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA761107 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2018-11-20 |
| Marketing End Date | 2021-11-30 |
| Ingredient | Strength |
|---|---|
| EMAPALUMAB | 10 mg/2mL |
| SPL SET ID: | 203459a5-9769-44a0-8396-43d110207ba9 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 66658-501 | GAMIFANT | (emapalumab-lzsg) |
| 66658-505 | GAMIFANT | (emapalumab-lzsg) |
| 66658-510 | GAMIFANT | (emapalumab-lzsg) |
| 72171-501 | GAMIFANT | (emapalumab-lzsg) |
| 72171-505 | GAMIFANT | (emapalumab-lzsg) |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() GAMIFANT 87283834 5505933 Live/Registered |
EMACO SA 2016-12-29 |